Thursday, November 09, 2017 12:18:18 AM
Matthew Frankel (Cowen)
. . . I Just want to know if there is any way you feel comfortable quantifying the revenue potential, revenue opportunity from BLA. The BLAs you expect to be filed over the next year, the commercialization opportunities to the next year. Anyway to puts some numbers around that? And what it means for you guys?
Mark Sawicki
Yeah, I can give some color on it. You know guys, so as we had stated, we anticipate an addition two to four filing next year which obviously would have a lead time in regards to commercialization. But I think using the same measure in particular for any of the autologous treatments as you would observe with either than Novartis or the Kite expectations which Jerry commented about in the earnings calls is probably reasonable. Ramp rate and timing would be similar to any of these types of launches. But we also have a number of programs which are allogeneic in nature and if those allogeneic therapies you know filed and are approved, the volumes of these units will be in order of magnitude or too higher than that of a say autologous therapy. So, we would anticipate seeing numbers that could easily drive into the $40 million to $60 million range at full absorption if they were approved and were approved through a broader application. And it depends on the nature of the therapy approved in the timing of it.
Is he talking about their client Tigenix (TiG) and Cx601? It’s an allogenic stem cell treatment for patients with Crohn's disease that could receive a decision by the CHMP at its next meeting December 11th-14th and then by the EMA in Q1 2018. In the U.S., this is one of the 20 phase 3 trials Cryoport supports that launched in June or July and has recently been granted orphan status by the FDA and now has an expedited pathway for the submission and review process. I think the trial was reduced from 52 to 24 weeks, so this may be one of the anticipated BLA filings next year. I don't think it's that large of a patient pop though.
I think Cryoport is also supporting another phase 2 trial for their allogeneic cardiac stem cells for acute myocardial infarction.
I think Bellicum's BPX-501 allogenic stem cell treatment is in a phase 2 trial that should have a read out next year but probably won't file until 2019.
Recent CYRX News
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/03/2024 08:23:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 11:11:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 09:28:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 06:55:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 12:00:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 09:17:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:34:57 PM
- Cryoport Reports Second Quarter 2024 Financial Results • PR Newswire (US) • 08/06/2024 08:15:00 PM
- Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes • PR Newswire (US) • 08/06/2024 08:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/02/2024 08:22:37 PM
- Cryoport to Report Second Quarter 2024 Financial Results on August 6, 2024 • PR Newswire (US) • 07/23/2024 12:30:00 PM
- Cryoport and Minaris Regenerative Medicine Form Strategic Partnership to Support Advancement of Cell and Gene Therapies • PR Newswire (US) • 06/20/2024 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/14/2024 08:31:02 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/30/2024 08:45:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 09:10:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 11:03:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 11:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 11:01:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 11:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 11:28:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:53:55 PM
- Cryoport Reports First Quarter 2024 Financial Results • PR Newswire (US) • 05/07/2024 08:08:00 PM
- Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024 • PR Newswire (US) • 04/30/2024 12:30:00 PM
- Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/12/2024 08:05:00 PM
- Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 • PR Newswire (US) • 02/27/2024 01:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM